UpToDate Lexidrug

At its core this is a curated drug reference, and the learned component sits in search. Wolters Kluwer says advanced machine learning powers Lexidrug's search results, and the Clinical Effectiveness terms that UpToDate, Inc. applies across its products add that search may run on third party functionality with its own software and models.

In use, search suggests drug names as a user types, offers alternatives for misspelled terms and can be narrowed to fields such as uses, adverse reactions or contraindications. The ranking comes with no stated training source, weighting or quality measure. Take the model away and the product keeps its value: monographs written by pharmacists and clinicians, interaction and IV compatibility tools, and calculators. Conversational drug answers built on Lexidrug content belong to a different product, UpToDate Expert AI, which has drawn on about 3,000 Lexidrug drug topics since November 2025.

Every result passes through a pharmacist or prescriber before anything reaches a patient. Lexidrug returns monographs, interaction results, compatibility answers and calculator outputs, and it writes no order, changes no dose and acts on no chart.

Its own terms call the content a tool to help clinicians reach decisions, tell prescribers to check each drug's product information sheet, especially for new, rarely used or narrow therapeutic range agents, and warn against relying on older versions. The broader Clinical Effectiveness terms bar using search for clinical purposes without review by a health professional. The weak point is search.

A ranking that puts the wrong monograph first, such as a sound alike drug name, comes with no described safeguard or signal to the user. Offline copies on a phone or a standalone workstation add a second risk, since a stale download can outlive an update.

The content behind Lexidrug has a clear lineage; the search behind it does not. A multidisciplinary team of pharmacists and clinicians writes the monographs and updates them continuously from medical and pharmaceutical literature, dedicated editorial teams maintain the dosing guidance, and the product terms say new releases come out periodically and older versions should not be relied on.

Search is described only as advanced machine learning, and the broader Clinical Effectiveness terms say a third party may supply it. The search model has no stated name, provider, version, training data or update schedule, and no change history tells a customer when ranking behavior shifted. For a reference opened at the point of care, which result appears first matters almost as much as what each monograph says.

An outside search provider may sit in the chain, unnamed. The Clinical Effectiveness terms that cover UpToDate products, Lexidrug among them, say search may run on third party functionality with its own software and models, and they bar using that search to process health information covered by HIPAA without an executed business associate agreement. Lexidrug's own terms are silent on who supplies search.

There is no subprocessor list, and the privacy notice refers only to unnamed service providers for hosting and supporting technology, alongside other Wolters Kluwer affiliates. What a query passes to the search provider, how long it is kept and whether it trains that provider's models all go unstated. Lexidrug Web Services, the hosted feed that carries drug information into other systems, names no hosting party either.

A 2016 independent comparison placed Lexi-Interact, the interaction checker inside Lexidrug, first among five programs. Kheshti, Aalipour and Namazi of Shiraz University of Medical Sciences, writing in the Journal of Research in Pharmacy Practice, tested 360 drug pairs drawn from pharmacy prescriptions and 40 known clinically important pairs, with a clinical pharmacist and Stockley's Drug Interactions as the reference.

Lexi-Interact judged 279 of 400 pairs correctly, or 69.8 percent, had the highest sensitivity at 0.77, tied Epocrates on accuracy at 250 of 400 points, and posted the best combined score, 370 of 534. The authors still advise pairing programs with a pharmacist's review. The version tested was a 2013 release run on an iPad. Fewer medication errors and lower cost, the benefits Lexidrug is sold on, come without an outcome study, and its machine learning search has no evaluation of its own.

Patient data is kept out by design, and usage data is not. The Clinical Effectiveness terms say UpToDate products are not intended to receive protected health information and bar users from entering it. What the service does collect is behavior: clicks, mouse movements, scrolling, keystrokes in fields that are not excluded, IP address and location.

UpToDate may deidentify and aggregate that information and owns the result, and it also owns the queries and search terms professional users submit. The privacy notice keeps personal information as long as its purposes require, with no period given, and counts improving products among those purposes. Whether queries train the third party search model is left open. No safety engineering is described: nothing covers guarding against a ranking error or how a safety event is handled.

The position is plain: Lexidrug is not built to handle protected health information. The statement sits in the Clinical Effectiveness terms, updated April 2026, which cover UpToDate products and say UpToDate and its licensors are not intended to receive, transmit, store or process PHI, so users may not enter it. Lexidrug's own terms are silent on PHI and apply the UpToDate privacy notice to the service.

The one exception is UpToDate Expert AI, where an organization can sign a business associate agreement written for that product. Lexidrug has no agreement of its own because it is not meant to see patient data. The open question is the EHR route. Lexidrug's Infobutton links are built from chart elements such as medications and orders, the same links for UpToDate carry patient context like age and gender, and nothing states what context reaches Lexidrug or how it is handled.

Neither Lexidrug nor UpToDate, Inc., the company that licenses it, comes with a SOC 2 report, ISO 27001 certificate, HITRUST certification or trust center. Wolters Kluwer does show ISO 27001 certificates for products in other divisions, such as its CCH Integrator tax platform, and those do not cover this one. The privacy notice describes an internal framework of policies, reasonable security standards and need to know access, with no outside audit behind it.

The license terms add account controls rather than assurance: shared logins are banned, and access can be cut off after concurrent logins, excessive searching or heavy download traffic. For a product embedded in Epic, MEDITECH and Cerner workflows and delivered through hosted web services, an independent audit of how the service is run is the missing piece.

Reference content for professionals is the stated position, and the product makes no device claim. Its own terms say the content describes basic principles of diagnosis and therapy, is no substitute for assessing the individual patient, and asks prescribers to confirm dosing against each drug's product information sheet.

The broader Clinical Effectiveness terms go further, calling the content generalized information not meant to take a patient's age, weight, conditions or other medications into account. The marketing pulls the other way, selling personalized medication dosing guidance and a patient specific approach.

In practice the dosing content is written for patient groups, such as renal or hepatic impairment, obesity, children or neonates, and a clinician reads the basis for each recommendation before applying it.

Corporate policy is the whole of it. Wolters Kluwer's AI principles apply across its businesses, and nothing specific to Lexidrug's search model sits beneath them: no evaluation of ranking quality, no test of how search handles brand versus generic names, the more than 500,000 international brand names in the database or misspelled queries, and no comparison of results across patient groups. The content raises a coverage question of its own.

Lexidrug gives dosing for pediatric, neonatal, geriatric and pregnant patients, groups where trial evidence is often thin, and a reader gets no view of how a monograph flags weaker evidence for them or how search ranks queries about them.

Nothing stands behind an answer beyond the references a pharmacist can trace. Monographs carry literature references, so a user can follow a recommendation to its sources, and the product terms tell prescribers to confirm dosing against each drug's product information sheet.

Lexidrug's own terms supply the content as is, disclaim accuracy, correctness and completeness, and cap liability for clinician users at the license fees paid in the prior twelve months, or $100 for patients given access by a provider. The broader Clinical Effectiveness terms set the cap at the greater of a year of fees or $100, and say warranties, indemnities and performance commitments in an enterprise master agreement do not reach search or generative outputs. No error rate, correction commitment or route for a patient harmed by a wrong entry comes with the product.

Content runs one way into named record systems, with customers on record. In Epic, Lexidrug appears as an embedded search link in the clinical references toolbar, drug reference links from the MAR and order entry, boxed warning links, and Active Guidelines Infobutton links in the problem list, health maintenance, order entry and medication screens.

Cerner Millennium carries a toolbar search link with autocomplete, and MEDITECH reaches it through HL7 Infobutton across Magic, Client/Server, 6.x and Expanse. Yuma Regional Medical Center and Froedtert and the Medical College of Wisconsin are quoted on their integrations, and since July 2026 eligible Epic customers, including rural hospitals, federally qualified health centers and tribal health organizations, can take Lexidrug in a turnkey bundle with Medi-Span and UpToDate Patient Education. Hosted Web Services feeds drug data keyed to GPI, NDC and DIN codes into other workflows. Everything displays inside the record; nothing writes back.

Lexidrug reaches users several ways, and none comes with a committed location. Clinicians use it on the web, inside Epic, MEDITECH and Cerner, through hosted Lexidrug Web Services, and in a mobile app that can download the full database for offline use, which keeps a pharmacist covered during a code blue or an outage. The clinician license terms also provide for a standalone workstation copy with no internet access.

No hosting provider, region or availability commitment is given for the online service or the web services. The privacy notice says transfers between countries rely on safeguards such as EU model clauses or binding corporate rules, and users in the European Economic Area and the United Kingdom are covered by a separate data protection annex.

The routes to buy are clear even though Lexidrug itself carries no list price. Individuals subscribe online through the UpToDate store; independent community pharmacies of one to ten stores and independent medical and dental practices buy through a sales line; hospitals, institutions and groups of 20 or more clinicians buy enterprise licenses through sales. Eligible Epic customers can take it in a turnkey bundle with Medi-Span and patient education.

Part of the content does carry a price: the $579 a year UpToDate personal subscription includes select Lexidrug monographs and a drug interaction checker. What a full Lexidrug subscription, Web Services or an enterprise license costs, and what drives enterprise pricing, is left to the sales conversation.

Packages are cut by role, with outside testing behind one tool. They serve hospital pharmacists, retail pharmacists through Facts and Comparisons, physicians, nurse practitioners, physician assistants, nursing, and dental practices through Lexidrug for Dentistry. Content spans adult, pediatric, neonatal, geriatric and pregnant patients, toxicology, infectious disease, drug allergy, genetic variation and international drugs.

Individual subscriptions reach independent community pharmacies of one to ten stores, and whole systems run it too: Manitoba's Shared Health made Lexidrug its primary provincial medication information tool in May 2026, replacing Micromedex. Researchers at Shiraz University of Medical Sciences tested the interaction checker on drug pairs from pharmacy prescriptions. That testing covers the interaction checker alone, in a 2013 mobile version, not the pediatric and neonatal dosing content, the dental package or search.